 Intec Pharma Ltd. NASDAQ: NTEC Intec or the Company today announces that the Company has entered into an Ordinary Shares Purchase Agreement for 10.0 million with Aspire Capital Fund, LLC Aspire Capital, a Chicago-based institutional investor. Under the terms of the Agreement, Aspire Capital is committed to purchase up to 10.0 million of Intec Pharmas ordinary shares over a 30-month period extending into 2022, subject to certain terms and conditions. There are no warrants, derivatives, or other share classes associated with this agreement. Proceeds from the Agreement will be used to fund the Companys research and development activites, for working capital and for general corporate purposes. 